RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
about
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response.The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma.
P2860
RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
RAS/MAPK pathway hyperactivati ...... entiated pleomorphic sarcomas.
@en
RAS/MAPK pathway hyperactivati ...... entiated pleomorphic sarcomas.
@nl
type
label
RAS/MAPK pathway hyperactivati ...... entiated pleomorphic sarcomas.
@en
RAS/MAPK pathway hyperactivati ...... entiated pleomorphic sarcomas.
@nl
prefLabel
RAS/MAPK pathway hyperactivati ...... entiated pleomorphic sarcomas.
@en
RAS/MAPK pathway hyperactivati ...... entiated pleomorphic sarcomas.
@nl
P2093
P2860
P50
P356
P1433
P1476
RAS/MAPK pathway hyperactivati ...... rentiated pleomorphic sarcomas
@en
P2093
Claudia Valverde
Cleofé Romagosa
César Serrano
Manuel Pérez
Ramona Vergés
Rosa Domínguez
Rosa Somoza
Sara Simonetti
Teresa Moliné
P2860
P304
P356
10.1002/CNCR.29733
P407
P577
2015-10-19T00:00:00Z